Veradermics R&D chief reports zero MANE holdings

Veradermics, Inc (MANE) had an initial statement of beneficial ownership filed for David Hollander, who serves as Chief R&D Officer.

Rhea-AI Filing Summary

Veradermics, Inc (MANE) had an initial statement of beneficial ownership filed for David Hollander, who serves as Chief R&D Officer. The filing reports no transactions and no beneficial ownership positions in Veradermics securities as of the reporting date.

Key Figures

Net buy/sell shares: 0 shares

1 metrics

Net buy/sell shares 0 shares Transaction summary for David Hollander on initial Form 3

Key Terms

Form 3, beneficial ownership, reporting person

3 terms

Form 3 regulatory

"The company submitted a <b>Form 3</b>, which is an initial statement"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership regulatory

"an initial statement of <b>beneficial ownership</b> for officers, directors"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"The insider is David Hollander, the <b>reporting person</b> on the Form 3"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider in Veradermics, Inc (MANE)'s latest Form 3 filing?

The insider is David Hollander, who is reported as the Chief R&D Officer of Veradermics, Inc. The Form 3 identifies him as an officer but not as a director or ten percent owner.

What type of filing did Veradermics, Inc (MANE) submit for David Hollander?

The company submitted a Form 3, which is an initial statement of beneficial ownership for officers, directors, or large shareholders when they first become insiders of Veradermics, Inc.

Does the Form 3 for MANE report any stock transactions by David Hollander?

No. The Form 3 reports no transactions by David Hollander. The transaction summary shows zero buys, zero sells, zero derivative exercises, and no other transaction activity.

Does the Form 3 show any beneficial ownership by David Hollander in MANE?

The Form 3 reports no beneficial ownership positions for David Hollander, with zero holding entries and no derivative positions listed in the filing data.

Is there any Rule 10b5-1 trading plan noted in the MANE Form 3?

No. The Form 3 data show the Rule 10b5-1 plan indicator as null, and there are no transactions or footnotes indicating that any pre-arranged trading plan applies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 07:05 PM Accepted by SEC EDGAR 08/20/2026 - 07:04 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hollander David

(Last) (First) (Middle)

470 JAMES ST.

(Street)

NEW HAVEN CONNECTICUT 06513

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/10/2026

3. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Michael Greco, Attorney-in-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)